RedHill Biopharma (RDHL) Tops Q1 Loss Views

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. SAP
7. CSX
8. LRCX
9. KNX
10. SPY

Go back to RedHill Biopharma (RDHL) Tops Q1 Loss Views

RedHill Biopharma Reports 2016 Second Quarter Financial Results

July 26, 2016 7:01 AM EDT

RedHill maintains a strong and debt-free balance sheet with $47.7 million in cash at the end of the second quarter, allowing the Company to continue to diligently execute its three ongoing Phase III gastrointestinal disease programs in the U.S. as well as additional clinical programsRecent key milestones include: First patients dosed in the Phase II study with BEKINDA for diarrhea-predominant irritable bowel syndrome (IBS-D)Positive Type B meeting with the FDA supporting the planned confirmatory Phase III study with RHB-105 for H.... More